NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rocket Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.80 -0.97 (-4.08 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$22.40Now: $22.80▼$23.8350-Day Range$20.48MA: $22.59▼$25.1152-Week Range$10.76Now: $22.80▼$27.59Volume158,100 shsAverage Volume354,294 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/ABeta2.86 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT Previous Symbol CUSIPN/A CIK1281895 Webhttp://www.rocketpharma.com/ Phone646-440-9100Debt Debt-to-Equity Ratio0.20 Current Ratio11.07 Quick Ratio11.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book5.10Profitability EPS (Most Recent Fiscal Year)($1.89) Net Income$-74,520,000.00 Net MarginsN/A Return on Equity-39.80% Return on Assets-30.75%Miscellaneous Employees33 Outstanding Shares50,376,000Market Cap$1.15 billion Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive RCKT News and Ratings via Email Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RCKT Rates by TradingView Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals Inc (NASDAQ:RCKT) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.11. View Rocket Pharmaceuticals' Earnings History. When is Rocket Pharmaceuticals' next earnings date? Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Rocket Pharmaceuticals. What price target have analysts set for RCKT? 7 brokers have issued 1 year price objectives for Rocket Pharmaceuticals' stock. Their forecasts range from $27.00 to $42.00. On average, they anticipate Rocket Pharmaceuticals' stock price to reach $35.00 in the next year. This suggests a possible upside of 53.5% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals. What is the consensus analysts' recommendation for Rocket Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals. Has Rocket Pharmaceuticals been receiving favorable news coverage? News headlines about RCKT stock have been trending very negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Rocket Pharmaceuticals. Who are some of Rocket Pharmaceuticals' key competitors? Some companies that are related to Rocket Pharmaceuticals include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT), Zai Lab (ZLAB), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE) and Blueprint Medicines (BPMC). What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Alibaba Group (BABA), NVIDIA (NVDA), Pfizer (PFE), Amarin (AMRN), Energy Transfer LP Unit (ET), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Home Depot (HD) and Cisco Systems (CSCO). Who are Rocket Pharmaceuticals' key executives? Rocket Pharmaceuticals' management team includes the folowing people: Mr. Gaurav Shah, CEO, Pres & Director (Age 44)Mr. John C. Militello, Controller (Age 46)Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO & Head of Devel. (Age 39)Dr. Claudine Prowse Ph.D., Sr. VP of Corp. Strategy & IROMr. Jonathan Schwartz, Chief Medical Officer (Age 55) Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (4.45%), FMR LLC (2.53%), Lord Abbett & CO. LLC (2.03%), State Street Corp (1.81%), Goldman Sachs Group Inc. (1.37%) and Geode Capital Management LLC (0.93%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel, Naveen Yalamanchi and Rtw Investments, Lp. View Institutional Ownership Trends for Rocket Pharmaceuticals. Which major investors are selling Rocket Pharmaceuticals stock? RCKT stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, FMR LLC, State Street Corp, Schonfeld Strategic Advisors LLC, Rafferty Asset Management LLC, Franklin Resources Inc., Credit Suisse AG and Citigroup Inc.. View Insider Buying and Selling for Rocket Pharmaceuticals. Which major investors are buying Rocket Pharmaceuticals stock? RCKT stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Farallon Capital Management LLC, Perceptive Advisors LLC, Blair William & Co. IL, Jefferies Group LLC, Monashee Investment Management LLC, Goldman Sachs Group Inc. and California Public Employees Retirement System. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel and Rtw Investments, Lp. View Insider Buying and Selling for Rocket Pharmaceuticals. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $22.80. How big of a company is Rocket Pharmaceuticals? Rocket Pharmaceuticals has a market capitalization of $1.15 billion. The biotechnology company earns $-74,520,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe.View Additional Information About Rocket Pharmaceuticals. What is Rocket Pharmaceuticals' official website? The official website for Rocket Pharmaceuticals is http://www.rocketpharma.com/. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected] MarketBeat Community Rating for Rocket Pharmaceuticals (NASDAQ RCKT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 285 (Vote Outperform)Underperform Votes: 205 (Vote Underperform)Total Votes: 490MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: What is the accumulation/distribution indicator?
